U.S. markets open in 9 hours 22 minutes
  • S&P Futures

    3,652.75
    -7.75 (-0.21%)
     
  • Dow Futures

    29,689.00
    -115.00 (-0.39%)
     
  • Nasdaq Futures

    12,439.25
    -13.00 (-0.10%)
     
  • Russell 2000 Futures

    1,832.70
    -2.80 (-0.15%)
     
  • Crude Oil

    44.15
    -0.40 (-0.90%)
     
  • Gold

    1,812.50
    -6.40 (-0.35%)
     
  • Silver

    23.82
    -0.27 (-1.12%)
     
  • EUR/USD

    1.2077
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.77
    +0.20 (+0.97%)
     
  • GBP/USD

    1.3417
    -0.0006 (-0.05%)
     
  • USD/JPY

    104.3900
    +0.0740 (+0.07%)
     
  • BTC-USD

    18,500.02
    -196.16 (-1.05%)
     
  • CMC Crypto 200

    363.29
    -16.57 (-4.36%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,829.69
    +42.15 (+0.16%)
     

Bio-Rad Laboratories: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 86.34% year over year to $3.00, which beat the estimate of $1.80.

Revenue of $647,263,000 rose by 15.45% year over year, which beat the estimate of $570,580,000.

Guidance

Bio-Rad Laboratories hasn't issued any earnings guidance for the time being.

View more earnings on BIO

Bio-Rad Laboratories hasn't issued any revenue guidance for the time being.

Recent Stock Performance

52-week high: $592.66

Company's 52-week low was at $309.38

Price action over last quarter: Up 8.22%

Company Overview

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.